ORG
Controversy Surrounds FDA’s Fast-Track Approval of Sarepta’s Duchenne Muscular Dystrophy Gene Therapy
FDA, Sarepta Therapeutics, Duchenne Muscular Dystrophy (DMD), gene therapy, accelerated approval, controversy, clinical trials, efficacy, safety, patient advocacy, regulatory process.
Novo Holdings Supports Reunion Neuroscience’s $103M Series A Funding for Pioneering Psychedelic Clinical Trials
Novo Holdings, Reunion Neuroscience, Series A funding, psychedelic clinical trials, mental health treatments, mental health innovation, venture capital, biotechnology, healthcare investments.
Moderna Terminates Gene Editing Partnership, Shifts Focus to mRNA Technology
Moderna, Metagenomi, gene editing, partnership, mRNA technology, biotechnology, biobucks, deal termination
BridgeBio Secures $200 Million from Venture Capitalists to Propel Oncology Spinout Beyond KRAS Class
BridgeBio, venture capital, oncology, spinout, KRAS class, cancer treatment, biotechnology, drug development, investment, healthcare.
Moderna Maintains Long-Term Vision, Terminates Collaboration with Metagenomi
Moderna, first-quarter update, long-term strategy, Metagenomi, collaboration termination
Ingrezza, a Neurocrine Biosciences Drug, Receives FDA Approval for Tardive Dyskinesia Treatment
Neurocrine Biosciences, Ingrezza, FDA approval, tardive dyskinesia, neuropsychiatric disorder, valbenazine, first-of-its-kind treatment.
Amwell Reports Mixed Q1 Results with Decreased Sales but Narrowed Net Loss
Amwell, Q1 results, sales, net loss, telehealth, digital healthcare
FDA Grants Full Approval to Pfizer’s Tivdak for Advanced Cervical Cancer Treatment
FDA, Pfizer, Tivdak, full approval, advanced cervical cancer, treatment, regulatory tracker
The Closure of Walmart Health Highlights Significant Hurdles for Retail Health Innovators
Walmart Health, retail health, disruptors, challenges, closure, innovation, healthcare, accessibility, competition, patient engagement, healthcare landscape.
GSK’s Vaccine Sales Surge Continues, Boosting 2024 Outlook
GSK, GlaxoSmithKline, vaccine sales, 2024 forecasts, pharmaceutical industry, revenue growth, COVID-19 vaccines, Shingrix, healthcare sector